Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide,
methylprednisolone, cytarabine and cisplatin (ESHAP). Clinical efficacy and toxicity of this
ESHAOX salvage regimen will be evaluated in refractory or relapsed non-Hodgkin's lymphoma
patients.